PYPD Stock Overview
A clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
My Notes
Capture your thoughts, links and company narrative
PolyPid Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.97 |
| 52 Week High | US$9.20 |
| 52 Week Low | US$2.37 |
| Beta | 1.33 |
| 1 Month Change | -15.26% |
| 3 Month Change | -17.96% |
| 1 Year Change | -22.25% |
| 3 Year Change | -98.27% |
| 5 Year Change | n/a |
| Change since IPO | -99.48% |
Recent News & Updates
Recent updates
PolyPid set to cut 20% jobs
Oct 20PolyPid's surgical site infections treatment eligible for marketing nod submission in EU
Sep 28PolyPid sheds 75% as lead candidate fails in Phase 3 trial for post-surgical infections
Sep 02PolyPid GAAP EPS of -$1.23 misses by $0.60
Aug 10PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe
Aug 03PolyPid: Strong Pipeline, Close Catalysts
Apr 19Will PolyPid (NASDAQ:PYPD) Spend Its Cash Wisely?
Mar 18
Here's Why We're Watching PolyPid's (NASDAQ:PYPD) Cash Burn Situation
Nov 08We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth
Jul 15Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation
Mar 09PolyPid's oncoplex cancer program shows encouraging action in animal study
Dec 22PolyPid launches second late-stage trial with D-PLEX100 in surgical infections
Dec 16PolyPid pops 24% after D-PLEX100 nabs accelerated review in U.S. for preventing surgical infections
Nov 24Shareholder Returns
| PYPD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -15.1% | 2.9% | 2.8% |
| 1Y | -22.3% | 8.8% | 24.5% |
Return vs Industry: PYPD underperformed the US Pharmaceuticals industry which returned 10% over the past year.
Return vs Market: PYPD underperformed the US Market which returned 24.8% over the past year.
Price Volatility
| PYPD volatility | |
|---|---|
| PYPD Average Weekly Movement | 13.1% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PYPD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PYPD's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 61 | Dikla Czaczkes Akselbrad | www.polypid.com |
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer.
PolyPid Ltd. Fundamentals Summary
| PYPD fundamental statistics | |
|---|---|
| Market cap | US$20.21m |
| Earnings (TTM) | -US$26.86m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs PYPD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PYPD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$26.86m |
| Earnings | -US$26.86m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.95 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 357.1% |
How did PYPD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 05:50 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PolyPid Ltd. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Balaji Prasad | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |
| Brandon Folkes | Cantor Fitzgerald & Co. |